stockrowElanco Animal Health Incorporated
ELAN Healthcare Drug Manufacturers Specialty & Generic
Elanco Animal Health Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 6.22% from fiscal 2024.
- Revenue
- +10.2%
- EPS
- +450.0%
- Free cash flow
- +35.6%
- Total debt
- −6.91%
Quarter to June 2026, against a year earlier
Follow ELAN
Alert me
Elanco Animal Health Incorporated (ELAN) EPS (diluted)
Elanco Animal Health Incorporated's EPS (diluted) for fiscal 2025 was −$0.47, compared with $0.68 in fiscal 2024. Over the twelve months to 30 June 2026 it was −$0.41. Over the past ten years it has ranged from −$2.50 (fiscal 2023) to $0.68 (fiscal 2024); the current reading is higher than 50% of that period. Elanco Animal Health Incorporated ranks 37th of 75 Drug Manufacturers Specialty & Generic companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$0.47 | — |
| FY2024 | $0.68 | — |
| FY2023 | −$2.50 | — |
| FY2022 | −$0.15 | — |
| FY2021 | −$0.97 | — |
| FY2020 | −$1.27 | — |
| FY2019 | $0.18 | (35.71%) |
| FY2018 | $0.28 | — |
| FY2017 | −$1.06 | — |
| FY2016 | −$0.16 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | $0.11 | 0.00% |
| Mar 2026 | $0.11 | — |
| Dec 2025 | −$0.56 | — |
| Sep 2025 | −$0.07 | — |
| 31 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| NBIX Neurocrine Biosciences, Inc. compare | $6.74 |
| LNTH Lantheus Holdings, Inc. compare | $4.06 |
| KNSA Kiniksa Pharmaceuticals International, plc compare | $1.30 |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | $0.52 |
| RDY Dr. Reddy's Laboratories Ltd compare | $0.33 |
| ALKS Alkermes plc compare | −$0.01 |
| ELAN Elanco Animal Health Incorporated | −$0.41 |
| VTRS Viatris Inc. compare | −$0.53 |
| HIMS Hims & Hers Health, Inc. compare | −$0.63 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on ELAN
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement